Abstract
Aim:
To evaluate the pharmacokinetic interactions between theophylline and antofloxacin in vivo and in vitro.
Methods:
A randomized, 5-day treatment and 3-way crossover design was documented in 12 healthy subjects. The subjects were orally administered with antofloxacin (400 mg on d 1 and 200 mg on d 2 to 5), theophylline (100 mg twice a day and morning dose 200 mg on d 1 and 5), or theophylline plus antofloxacin. The plasma and urinary pharmacokinetics of antofloxacin and theophylline were characterized after the first and last dose. The effect of antofloxacin on theophylline metabolism was also investigated in pooled human liver microsomes.
Results:
The 5-day treatment with antofloxacin significantly increased the area of the plasma concentration-time curve and peak plasma concentration of theophylline, accompanied by a decrease in the excretion of theophylline metabolites. On the contrary, theophylline did not affect the pharmacokinetics of antofloxacin. In vitro studies using pooled human hepatic microsomes demonstrated that antofloxacin was a weak reversible and mechanism-based inhibitor of CYP1A2. The clinical interaction between theophylline and antofloxacin was further validated by the in vitro results.
Conclusion:
The results showed that antofloxacin increases the plasma theophylline concentration, partly by acting as a mechanism-based inhibitor of CYP1A2.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ye H, Wu JM, Yang YS, Chen KX, Ji RY . Antibacterial activities of the derivatives-YH54 and YH57 of levofloxacin in vitro. Chin Pharmacol Bull 2002; 18: 112–3.
Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, et al. Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 2008; 46: 172–9.
Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, et al. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008; 29: 167–72.
Gundert-Remy U, Hildebrandt R, Hengen N, Weber E . Non-linear elimination processes of theophylline. Eur J Clin Pharmacol 1983; 24: 71–8.
Tang-Liu DD, Williams RL, Riegelman S . Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31: 358–69.
Campbell ME, Grant DM, Inaba T, Kalow W . Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metab Dispos 1987; 15: 237–49.
Ha HR, Chen J, Freiburghaus AU, Follath F . Metabolism of theophylline by cDNA expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321–6.
Sarkar MA, Hunt C, Guzelian PS, Karnes HT . Characterization of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20: 31–7.
Tjia JF, Colbert J, Back DJ . Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276: 912–7.
Bachmann K, White D, Jauregui L, Schwartz JI, Agrawal NG, Mazenko R, et al. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 2003; 43: 1082–90.
Wijnands WJA, Van Herwaarden CLA, Vreeet TB . Enoxacin raises plasma theophylline concentrations. Lancet 1984; 2: 108–9.
Edwards DJ, Bowles SK, Svensson CK, Rybak MJ . Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet 1988; 15: 194–204.
Fuhr U, Anders EM, Mahr G, Sörgel F, Staib AH . Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942–8.
Loi CM, Parker BM, Cusack BJ, Vestal R . Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol 1993; 36: 195–200.
Matuschka PR, Vissing RS . Clinafloxacin-theophylline drug interaction. Ann Pharmacother 1995; 29: 378–80.
Zhang L, Wei MJ, Zhao CY, Qi HM . Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in liver microsomes. Acta Pharmacol Sin 2008; 29: 1507–14.
Zhu Q, Liao J, Xie L, Wang GJ, Liu XD . Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 2009; 39: 293–301.
Nie SL, Liu HY, Xie L . Reversed-phase high performance liquid chromatographic method for simultaneous determination of theophylline and its two metabolites in human urine. Chin J Clin Pharmacol Ther 2009; 14: 1386–91.
Pang XY, Xie L, Xu X, Liu HY, Liu L, Liu XD . Pharmacokinetics of ATFX in rats coadministered with non-steroidal anti-inflammatory drugs. Chin J New Drugs 2007; 16: 600–3.
Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 1999; 65: 262–74.
Mayhew BS, Jones DR, Hall SD . An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031–7.
Wang YH, Jones DR, Hall SD . Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32: 259–66.
Fowler S, Zhang H . In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 2008; 10: 410–24.
Sarkar M, Polk RE, Guzelian PS, Hunt C, Karnes HT . In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother 1990; 34: 594–9.
Kim EJ, Suh OK, Lee MG . Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci 2003; 72: 1231–45.
Niki Y, Watanabe S, Yshida K, Miyashita N, Nakajima M, Matsushima T . Effect of pazufloxacin mesilate on the serum concentration of theophylline. J Infect Chemother 2002; 8: 33–6.
Niki Y . Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother 2002; 8: 1–18.
Fairman DA, Collins C, Chapple S . Progress curves analysis of CYP1A2 inhibition: a more information approach to assessment of mechanism-based inactivation? Drug Metab Dispos 2007; 35: 2159–65.
Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD . Mechanism-based inhibition of human liver microsomal cytochromes P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352–60.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y . Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387–411.
Ito K, Iwatsubo T, Kanamitsu S, Itoh T . Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003; 31: 945–54.
Antoniou T, Gomes T, Mamdani MM, Juurlink DN . Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J Clin Pharmacol 2011; 67: 521–6.
Acknowledgements
This work was supported by the “Eleventh five-year Plan”–Technical Platform for Drug Development from the Ministry of Science and Technology of the People's Republic of China (No 2009ZX09304-001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, L., Pan, X., Liu, Hy. et al. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin 32, 1285–1293 (2011). https://doi.org/10.1038/aps.2011.78
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2011.78
Keywords
This article is cited by
-
Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China
Digestive Diseases and Sciences (2022)
-
Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats
Acta Pharmacologica Sinica (2016)
-
Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers
Clinical Pharmacokinetics (2016)
